Intuitive Surgical reported fourth-quarter 2025 earnings on Wednesday that handily beat Wall Street expectations, driven by strong procedure growth and accelerating adoption of its next-generation Da Vinci 5 surgical robot system. The results reinforced the company's dominant position in the robotic surgery market and its ability to maintain premium growth despite broader healthcare spending pressures.
Earnings Beat Estimates
The company reported non-GAAP earnings of $2.53 per diluted share, exceeding the consensus estimate of $2.25 by approximately 12%. This compared favorably to earnings of $2.21 per share in the fourth quarter of 2024, representing 14% year-over-year growth.
Revenue reached $2.87 billion for the quarter, in line with analyst expectations and up 19% from $2.41 billion in the year-ago period. The strong top-line performance was driven by robust procedure volumes and increased system placements.
Da Vinci 5 Adoption Accelerates
Perhaps the most significant highlight of the quarter was the rapid adoption of Intuitive's newest platform, the Da Vinci 5 surgical system. The company placed 303 Da Vinci 5 units during the quarter, up dramatically from 174 placements in the third quarter—a 74% sequential increase.
The Da Vinci 5 represents a generational upgrade with enhanced capabilities including force feedback, improved visualization, and expanded reach. Its strong reception suggests hospitals are willing to invest in premium surgical technology despite the challenging capital equipment environment.
Total system placements reached 532 for the quarter, compared with 493 in the fourth quarter of 2024. Intuitive's installed base grew to 11,106 systems worldwide, an increase of 12% from 9,902 systems a year earlier.
Procedure Growth Remains Strong
Worldwide procedures using Intuitive's systems grew approximately 18% year-over-year in the fourth quarter, combining both the flagship Da Vinci surgical platform and the newer Ion lung biopsy system. Da Vinci procedures specifically increased approximately 17%, while Ion procedures surged 44% as that platform continues its market penetration.
"Physicians used Intuitive's systems to treat more than 3.1 million patients in 2025, reflecting the continued trust that surgeons and hospitals place in our technology to deliver better outcomes."
— Intuitive Surgical Management
For the full year, total procedures grew 19% and total revenue increased 21%, demonstrating that robotic surgery adoption remains in a secular growth phase despite the company's already substantial market presence.
Margin Performance and Tariff Impact
Despite headwinds from tariffs on components and finished goods, Intuitive managed to improve its profitability. Pro forma operating margin expanded approximately 70 basis points to 37% for the full year 2025, reflecting strong operating leverage and disciplined cost management.
The company noted that tariffs represented a modest drag on results, with management estimating an impact of approximately 1.2% of revenue. However, pricing actions and efficiency improvements more than offset this headwind.
2026 Guidance
Looking ahead, Intuitive projected worldwide Da Vinci procedure growth of approximately 13% to 15% for 2026, a moderation from the 18% growth achieved in 2025. Management characterized this as appropriately conservative given macroeconomic uncertainty and the law of large numbers as the company's procedure base expands.
Non-GAAP gross profit margin is expected to be within a range of 67% to 68% of revenue in 2026, roughly in line with the 67.6% achieved in 2025. This guidance incorporates continued tariff impacts of approximately 1.2% of revenue.
Analyst Reaction
Wall Street analysts remain overwhelmingly positive on Intuitive Surgical, with a Strong Buy consensus rating based on 16 Buy recommendations and just 4 Holds. The average price target of $637.32 implies approximately 21% upside from current levels.
The bullish sentiment reflects confidence in Intuitive's competitive moat, recurring revenue model, and multi-year growth runway as robotic surgery penetration increases across surgical specialties and geographies. The company faces limited direct competition, with only Medtronic's Hugo system representing a meaningful challenger in the general surgery market.
Competitive Positioning
Intuitive's results underscore the company's ability to maintain pricing power and market leadership even as competition has intensified. The Da Vinci 5 launch has been particularly important in this regard, giving the company a clear technological lead over rivals and providing hospitals with a compelling reason to continue investing in the Intuitive ecosystem.
The Ion system's 44% procedure growth also highlights Intuitive's successful diversification beyond its core general surgery market into the lung biopsy space, where the minimally invasive robotic approach offers significant advantages over traditional bronchoscopy.
Investment Implications
For investors, Intuitive's results confirm the company's status as a premier growth stock within the medical device sector. The combination of double-digit procedure growth, expanding margins, and a long runway for robotic surgery adoption makes it a favored holding for growth-oriented healthcare portfolios.
The stock has been a strong performer, though its premium valuation leaves limited margin for error. Any deceleration in procedure growth or margin pressure could trigger meaningful multiple compression. For now, however, the company continues to execute at a high level, and Wednesday's results should reinforce investor confidence in the growth story.
